LRATD2 and breast carcinoma: Examination of clinical outcomes showed that FAM84B overexpression was associated with a significant decrease in breast cancer patient overall survival (104.3 months vs 159.7 months; P = 6.037 × 10− 6; Fig. 8d), whereas MYC overexpression was not significantly correlated with decreased survival with decreased survival (210.9 months vs 152.3 months; P = 504; Fig. 8e).